Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

Publication date

November 2018

DOI

10.6084/m9.figshare.7397864.v1

Abstract

Table S1. Target and NK cells treated with or without olaparib were analyzed for expression of cell surface markers by flow cytometry. (TIF 2079 kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

Open link

Publication date

November 2018

DOI

10.6084/m9.figshare.7397864.v1

Abstract

Table S1. Target and NK cells treated with or without olaparib were analyzed for expression of cell surface markers by flow cytometry. (TIF 2079 kb

Extracted data

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...

Additional file 15: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using a secondar...

Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...

Additional file 3: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

November 2018

Figure S1. Knock-out of TRAIL-R2 abrogates the olaparib-mediated increase in NK cell killing of DU14...

Additional file 1: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

November 2018

Table S2. Olaparid treated prostate cancer cells: Apoptotic Array Data. (TIF 4709 kb

Additional file 1: of Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Jiao Wang (47178)
Kyle Lupo (6050258)
Andrea Chambers (6050261)
Sandro Matosevic (1275933)

December 2018

Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...

Additional file1: of Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Natalie Eaton (5022989)
Hélène Cabanas (5022998)
Cassandra Balinas (5022995)
Anne Klein (5022992)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

March 2018

Figure S1. Representative flow cytometric plot of NK cell cytotoxic activity. PKH-26 was used to gat...

Additional file 2: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using a secondar...

Additional file 1 of Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

Li-Mei Chen (47129)
Pao-Pao Yang (13808953)
Aushia Tanzih Al Haq (13808954)
Pai-An Hwang (13808955)
You-Chen Lai (13808956)
Yueh-Shan Weng (6477854)
Michelle Audrey Chen (13808957)
Hsin-Ling Hsu (13808958)

September 2022

Additional file 1: Fig. S1. PD-L1 is suppressed by DBPR112, Oligo-Fucoidan and olaparib. PD-L1 level...

Additional file 2: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb

Additional file 3: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb

Additional file 1: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...

Additional file 1: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on unlabelled NK cells at 2â...

Additional file 9: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using primary TR...

Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...

Additional file 15: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using a secondar...

Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

November 2018

Figure S1. Knock-out of TRAIL-R2 abrogates the olaparib-mediated increase in NK cell killing of DU14...

Kathleen Fenerty (6020954)
Michelle Padget (6020960)
Benjamin Wolfson (6020966)
Sofia Gameiro (2852234)
Zhen Su (18658)
John Lee (254837)
Shahrooz Rabizadeh (152356)
Patrick Soon-Shiong (4179982)
James Hodge (6020972)

November 2018

Table S2. Olaparid treated prostate cancer cells: Apoptotic Array Data. (TIF 4709 kb

Additional file1: of Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Natalie Eaton (5022989)
Hélène Cabanas (5022998)
Cassandra Balinas (5022995)
Anne Klein (5022992)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

March 2018

Figure S1. Representative flow cytometric plot of NK cell cytotoxic activity. PKH-26 was used to gat...

Additional file 2: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using a secondar...

Additional file 1 of Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

Li-Mei Chen (47129)
Pao-Pao Yang (13808953)
Aushia Tanzih Al Haq (13808954)
Pai-An Hwang (13808955)
You-Chen Lai (13808956)
Yueh-Shan Weng (6477854)
Michelle Audrey Chen (13808957)
Hsin-Ling Hsu (13808958)

September 2022

Additional file 1: Fig. S1. PD-L1 is suppressed by DBPR112, Oligo-Fucoidan and olaparib. PD-L1 level...

Additional file 2: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S1. Immuno-phenotyping antibodies used for tumor flow cytometry. (DOCX 13 kb

Additional file 3: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb

Additional file 1: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...

Additional file 1: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on unlabelled NK cells at 2â...

Additional file 9: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using primary TR...

Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...

Additional file 15: of Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry

Cassandra Balinas (5022995)
Helene Cabanas (6691196)
Donald Staines (3525134)
Sonya Marshall-Gradisnik (3525122)

May 2019

Gating strategy for the analysis of TRPM2 and CD38 surface expression on NK subsets using a secondar...

Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Abstract

Extracted data

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Abstract

Extracted data

Related items

Related items

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Abstract

Extracted data

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Abstract

Extracted data

Related items

Related items

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Additional file 2: of Immunotherapy utilizing the combination of natural killerâ and antibody dependent cellular cytotoxicity (ADCC)âmediating agents with poly (ADP-ribose) polymerase (PARP) inhibition